[FORM 10-K (Mark One) x December 31, 2012 For the fiscal year ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [Product Research and Developmentreement Party A: Shaanxi Aoxing Pharmaceutical Party B: Lifeience Academy of Northwest University Party A and Party B reached the following R&Dreement regarding National Type I new medicinenshensu Borneol Ester through friendly negotiation: 2. Project research progress: (1) Party B has finished the research of DBZs activity, technical, quality standard and stability.] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to theorporation by reference in the Registration Statement on Forms S-8 (No. 333-161598) and S-8 (No. 333-183387) of Biostar Pharmaceuticals, of our reportted April 11, 2013 relating to thensolidated financial statements, which appears in the Annual Report on] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Mazars CPA Limited Mazars CPA Limited Certified Public Accountants Hong Kong April 11, 2013 ex23-2.htm 4 EX-23.2] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated.ted: April 15, 2013 Ronghua Wang Chief Executive Officer ex32-1.htm 7 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated.ted: April 15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) ex32-2.htm 8 EX-32.2]

[SUPPLEMENTAL AGREEMENT TO SHARE TRANSFER CONTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS CO., LTD. AND FORMER SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. Supplemental Agreement Transferee Party A: Shaanxi Aoxing Pharmaceuticals Co., Ltd. (hereinafter referred to as “ Transferors Party B: All Former Shareholders of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd. who]

[SUPPLEMENTALREEMENT TO SHARE TRANSFERNTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS AND FORMER SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS Supplementalreement Transferee Party A: Shaanxi Aoxing Pharmaceuticals (hereinafter referred to Transferors Party B:l Former Shareholders of Shaanxi Weinan Huaren Pharmaceuticals who are listed in Appendix I of thisreement (hereinafter referred to]